Daily non-political popular news in brief.

Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis

06-13-2007 · EurekAlert!

Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced the presentation of additional data that showed that the safety profile of Enbrel was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis who completed up to eight years of therapy. The study results will be presented at the European League Against Rheumatism Annual Congress, an international rheumatology meeting, in Barcelona, Spain.

Keywords: enbrel, safety, data, patients, juvenile, rheumatoid, arthritis, patient, arthriti

« Previous | Next »

Similar news on "Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis":

Disability from long-term rheumatoid arthritis reduced with biologic treatment
06-12-2007 · EurekAlert!
New data demonstrating the safety and efficacy of Enbrel (etanercept) in the treatment of rheumatoid arthritis (RA) patients over the long-term were presented today at the EULAR (European League Against Rheumatism) congress (1). Over 2,000 patients receiving this biologic treatment for up to nine years, saw improvements in disability whilst safety was also sustained over the long-term.
Similar news · Read more »
Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
11-13-2006 · EurekAlert!
Amgen (NASDAQ: AMGN) announced Enbrel (R) (etanercept) is the first biologic with published data to show sustained improvements in multiple efficacy measures in rheumatoid arthritis patients completing up to nine years of therapy. Current data suggest Enbrel is both effective and safe in long-term RA use, and the new data, presented at the American College of Rheumatology scientific meeting, provide a degree of reassurance that unexpected safety concerns do not appear to develop after nine years of use.
Similar news · Read more »
Latest data shows MabThera provides significant, sustained relief from symptoms of RA
06-13-2007 · EurekAlert!
New data presented at the EULAR meeting demonstrate that MabThera's effectiveness in relieving patients of the distressing symptoms of rheumatoid arthritis is sustained or further improved with subsequent courses of treatment, as is the number of patients achieving remission. Importantly, the safety profile of MabThera remained unchanged in patients who had received as many as seven courses of treatment at 6-12 month intervals.
Similar news · Read more »
Half of patients with active early rheumatoid arthritis achieved clinical remission
11-07-2007 · EurekAlert!
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced that data from a multicenter, randomized, double-blind trial of ENBREL plus methotrexate showed that 50 percent of patients with active early rheumatoid arthritis achieved clinical remission at one year.
Similar news · Read more »
Annals of Internal Medicine tip sheet for March 20, 2007
03-19-2007 · EurekAlert!
The following articles are featured in the upcoming Annals of Internal Medicine: "Flexible Use of Drugs with Close Patient Follow-up Can Successfully Control Rheumatoid Arthritis;" "Osteoporosis Drug Strengthens Bones in Men with Prostate Cancer," and "Experts Show Physicians How to Initiate and Carry Through Timely and Effective Discussions about Hospice with Dying Patients."
Similar news · Read more »
New study reveals gender disparity in anti-TNF treatment for rheumatoid arthritis
06-14-2007 · EurekAlert!
Findings reported today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, reveal a treatment disparity between female and male patients with rheumatoid arthritis. Data from a study at the Karolinska Institute, Sweden, show that women receive anti-TNFs -- very effective but expensive modern medications against this disease -- at a higher perceived level of disease activity, and when they are reporting more severe pain than their male counterparts.
Similar news · Read more »
First prospective study shows improvement of rheumatoid arthritis during pregnancy
06-14-2007 · EurekAlert!
Disease activity in patients with rheumatoid arthritis is significantly reduced during pregnancy, according to new data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. In the study, RA improved significantly from the first trimester to the third trimester of the participants' pregnancy and this effect extended into the postpartum stage.
Similar news · Read more »
One-fifth of patients in drug-free remission following early treatment with Infliximab and Methotrex
06-14-2007 · EurekAlert!
Early treatment with a combination of methotrexate and infliximab may be effective as remission induction therapy and alter the course of early rheumatoid arthritis, according to data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
Similar news · Read more »
Rheumatoid arthritis sends many into early retirement
02-04-2008 · EurekAlert!
A joint study on "The Burden of Rheumatoid Arthritis and Patient Access to Treatments" by authors from the Stockholm School of Economics, the University of Lund and the Medical University of Vienna has shown that the highest cost in rheumatoid arthritis results from patients having to leave the workforce early due to the disease. The study has just been published online in a supplement to Springer's The European Journal of Health Economics.
Similar news · Read more »
Obesity adds to the quality of life burden of rheumatoid arthritis
06-14-2007 · EurekAlert!
The global obesity epidemic was issued with a further health warning today -- that obesity exacerbates the quality of life of patients with rheumatoid arthritis. New data presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, shows that RA in obese patients is associated with worse quality of life outcomes on four key levels: pain, fatigue, physical function and overall utility scores.
Similar news · Read more »